Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells


Kusoglu A., Bagca B. , Ozates A. , Saydam G. , Avci C.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.20, ss.2316-2323, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 20 Konu: 18
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2174/1871520620666200218105159
  • Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Sayfa Sayıları: ss.2316-2323

Özet

Background: Ruxolitinib is a selective JAK1/2 inhibitor approved by the FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise. In multiple myeloma which is a cancer of plasma cells, the Interleukin-6/JAK/STAT pathway is emerging as a therapeutic target since the overactivation of the pathway is associated with poor prognosis.